| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0008 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.18 | 0.001 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |